Citigroup’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

Citigroup’s Portfolio GRNA Stock Details GRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,875	Closed	-$857	–	5893
2023 Q2	$857	Buy	2,875 +1,148	+66%	+$346	﹤0.01%	5343
2023 Q1	$747	Sell	1,727 -2,683	-61%	-$2.06K	﹤0.01%	5176
2022 Q4	$5.2K	Sell	4,410 -6,251	-59%	-$10.2K	﹤0.01%	5027
2022 Q3	$25K	Sell	10,661 -244	-2%	-$639	﹤0.01%	4665
2022 Q2	$24K	Buy	10,905 +5,189	+91%	+$36K	﹤0.01%	4903
2022 Q1	$55K	Buy	+5,716	New	+$51.2K	﹤0.01%	4688

Citigroup's GRNA Position: Q3 2023 in Review

Citigroup sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q3 2023, closing a stake of 2,875 shares — an estimated $857 sold.

Citigroup first reported a position in GRNA in Q1 2022 and held it in 6 quarters. The position peaked at $55K in Q1 2022. 0 funds tracked by Wall St. Rank hold GRNA as of Q3 2023.

Citigroup reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q3 2023 after selling out during the quarter.
Citigroup sold 2,875 GreenLight Biosciences Holdings, PBC Common Stock shares in Q3 2023, an estimated $857.
Citigroup first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q1 2022 and held it in 6 quarters.
Citigroup's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $55K in Q1 2022.
0 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q3 2023.

Based on Citigroup's 13F filing for Q3 2023, filed 9 Nov 2023.